News Release Details
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Apr 15, 2019
|
Rocket intends to use the net proceeds from the offering to further fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes.
The public offering is being made by Rocket pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements
Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the consummation of the offering, the terms of the offering, and the satisfaction of customary closing conditions with respect to the offering and the anticipated use of the net proceeds of the offering, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, changes as a result of market conditions or for other reasons, the risk that the offering will not be consummated, and the impact of general economic, industrial or political conditions in
View source version on businesswire.com: https://www.businesswire.com/news/home/20190415005810/en/
Source:
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
investors@rocketpharma.com